Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity

GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in Vaccines describing the immunogenic potential of NanoFlu™, Novavax’ recombinant seasonal influenza vaccine candidate adjuvanted with Matrix-M™. The publication provides an in-depth comparison of vaccine antibody responses in mice compared to similar antibody responses in human subjects from historic clinical trials, highlighting the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy. The publication is available online at https://www.mdpi.com/2076-393X/8/1/99/htm.
About NanoFlu™ and Matrix-M™NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes. Top-line data from Novavax’ ongoing Phase 3 clinical trial of NanoFlu is expected late in the first quarter of 2020.About NovavaxNovavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection, which is the second leading cause of death in children under one year of age worldwide. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.Forward-Looking StatementsStatements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including those regarding the potential for NanoFlu to offer broadly protective immunity and improved vaccine efficacy, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission (SEC). The results from our ongoing Phase 3 clinical trial of NanoFlu, which we expect to announce during the first quarter of 2020, represent the key near term risk for the commercial potential of this program, and Novavax does not yet know the results of that study. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.Contacts:Investors
Novavax, Inc.
Erika Trahan
[email protected]
240-268-2022Westwicke
John Woolford
[email protected]
443-213-0506Media
Brandzone/KOGS Communication
Edna Kaplan
[email protected]
617-974-8659
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow